Swedish bioprinting company CELLINK has been granted a patent from the Korean Intellectual Property Office for its Clean Chamber Technology, which enables bioprinting in a clean, sterile environment. The patent in question protects the technology—which is used in the company’s flagship BIO X and INKREDIBLE+ bioprinters—within the Korean market.
The patented technology by CELLINK is crucial to enabling desktop bioprinting while also ensuring sterility throughout the process—an important factor when producing anything related to the medical field. The patent from the Korean Intellectual Property Office helps to strengthen the company’s protection of its unique bioprinting platform and takes the company a step closer to its goal of protecting core technologies in the bioprinting field.
“We are extremely excited to have another granted patent for our revolutionary technology platform,” said Erik Gatenholm, CEO of CELLINK. “As a globally recognized leader in the field, it is essential for us to protect our technologies so that we can continue to offer the most innovative solutions to our customers and collaborators around the world. The Clean Chamber Technology is a unique, value adding feature that ensures that the printing environment inside the Bioprinter is kept sterile so that the user can reduce the risk of contaminations and protect the precious cells during the printing process.”
CELLINK also says it is currently conducting the patenting process in other countries to expand protections on its unique technology. In February 2019, the bioprinting company was also granted a patent for a method of printing tissue constructions by the Swedish Patent and Registration Office.
The Gothenburg-based company also holds a patent for its Cellulose Nanofibrillar Bioink material for bioprinting applications in cell culturing, tissue engineering and regenerative medicine.